Isoniazid monotherapy versus other monotherapies or combination chemotherapy for preventing active tuberculosis in HIV-negative persons

Sharma, Surendra Kumar; Sharma, Anju; Kadhiravan, Tamilarasu; Tharyan, Prathap

doi:10.1002/14651858.cd007545

Cited by 2 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The optimal duration of isoniazid as preventive therapy is nine months [116]; with addition of rifampicin or rifapentine this reduces to three months and rifampicin combined with pyrazinamide is effective after two months of administration (although unacceptable toxicity prevents widespread use of this regimen) [117]. There are several novel or re-purposed drugs in later stages of the TB drug pipeline [118] that have impressive sterilizing ability either alone or in drug combinations (usually in pyrazinamide-containing regimens).…”

Section: (C) Drugsmentioning

confidence: 99%

The ongoing challenge of latent tuberculosis

Esmail

Barry²,

Young

et al. 2014

Phil. Trans. R. Soc. B

281

236

View full text Add to dashboard Cite

The global health community has set itself the task of eliminating tuberculosis (TB) as a public health problem by 2050. Although progress has been made in global TB control, the current decline in incidence of 2% yr−1 is far from the rate needed to achieve this. If we are to succeed in this endeavour, new strategies to reduce the reservoir of latently infected persons (from which new cases arise) would be advantageous. However, ascertainment of the extent and risk posed by this group is poor. The current diagnostics tests (tuberculin skin test and interferon-gamma release assays) poorly predict who will develop active disease and the therapeutic options available are not optimal for the scale of the intervention that may be required. In this article, we outline a basis for our current understanding of latent TB and highlight areas where innovation leading to development of novel diagnostic tests, drug regimens and vaccines may assist progress. We argue that the pool of individuals at high risk of progression may be significantly smaller than the 2.33 billion thought to be immune sensitized by Mycobacterium tuberculosis and that identifying and targeting this group will be an important strategy in the road to elimination.

show abstract

Section: (C) Drugsmentioning

confidence: 99%

The ongoing challenge of latent tuberculosis

Esmail

Barry²,

Young

et al. 2014

Phil. Trans. R. Soc. B

281

236

View full text Add to dashboard Cite

show abstract

L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model

et al. 2022

View full text Add to dashboard Cite

Both active tuberculosis (TB) and asymptomatic latent Mycobacterium tuberculosis (M. tb) infection (LTBI) cause significant health burdens to humans worldwide. Individuals with immunocompromising health conditions, such as Type 2 Diabetes Mellitus (T2DM), have a weakened ability to control M. tb infection and are more susceptible to reactivation of LTBI to active diseases. T2DM cases are known to have glutathione (GSH) deficiency and impaired immune cell function, including the granulomatous response to M. tb infection. We have previously reported that liposomal glutathione (L-GSH) supplementation can restore the immune cell effector responses of T2DM cases. However, the effects of L-GSH supplementation on the bactericidal activities of first-line anti-TB drug rifampicin (RIF) against M. tb infection have yet to be explored. The aim of this study is to elucidate the effects of L-GSH supplementation in conjunction with RIF treatment during an active M. tb infection in a diabetic mouse model. In this study, we evaluated total and reduced levels of GSH, cytokine profiles, malondialdehyde (MDA) levels, M. tb burden, and granulomatous response in the lungs. We show that L-GSH supplementation caused a significant reduction in M. tb burden in the lungs, decreased oxidative stress, and increased the production of IFN-γ, TNF-α, IL-17, IL-10, and TGF-β1compared to the untreated mice. In addition, L-GSH supplementation in conjunction with RIF treatment achieved better control of M. tb infection in the lungs and significantly reduced the levels of oxidative stress compared to treatment with RIF alone. Moreover, L-GSH in conjunction with RIF significantly increased TGF-β1 levels compared to treatment with RIF alone. These findings suggest potential therapeutic benefits of L-GSH supplementation in conjunction with first-line antibiotic therapy against M. tb infection in individuals with T2DM.

show abstract

Isoniazid monotherapy versus other monotherapies or combination chemotherapy for preventing active tuberculosis in HIV-negative persons

Cited by 2 publications

References 14 publications

The ongoing challenge of latent tuberculosis

The ongoing challenge of latent tuberculosis

L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model

Contact Info

Product

Resources

About